<unk>  (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin, that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.<unk>  is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29. It is on the World Health Organization's List of Essential Medicines. In 2019, it was the 168th most commonly prescribed medication in the United States, with more than 3million prescriptions.
Insulin degludec
Insulin aspart
Insulin glulisine
Insulin detemir
Lente insulin
Insulin lispro
Insulin glargine
Ultralente insulin